Sequana Medical financials
Sequana Medical
8755009AN12Y4PEOII07 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Revenue | €712.2K | €922.7K |
| Cost of sales | €164.1K | €204.6K |
| Gross profit | €548.0K | €718.1K |
| Other income | €629.3K | €530.2K |
| Operating expenses | €30.0M | €29.3M |
| Operating profit (EBIT) | -€28.9M | -€28.1M |
| Net finance income / (cost) | -€3.2M | -€2.3M |
| Finance costs | €4.3M | €2.7M |
| Income tax expense | €465.6K | €386.6K |
| Profit for the year | -€32.6M | -€30.8M |
| — attributable to owners | -€32.6M | -€30.8M |
| Total comprehensive income | -€33.0M | -€29.6M |
| Per share | ||
| Basic EPS | €-1.22 | €-1.35 |
| Free cash flow / share | €-1.12 | €-1.24 |
| Cash flow statement | ||
| Net cash from operating activities | -€29.1M | -€27.5M |
| Net cash from investing activities | -€721.4K | -€653.1K |
| Purchase of PP&E (capex) | €710.8K | €676.7K |
| Net cash from financing activities | €13.5M | €37.3M |
| Proceeds from borrowings | €0 | €9.6M |
| Repayments of borrowings | €982.4K | €0 |
| Lease liability payments | €414.0K | €407.2K |
| Net change in cash | -€16.3M | €9.2M |
| Balance sheet | ||
| Total assets | €10.1M | €26.0M |
| Non-current assets | €3.8M | €2.9M |
| Property, plant & equipment | €2.3M | €2.1M |
| Current assets | €6.3M | €23.1M |
| Inventories | €2.3M | €2.6M |
| Trade & other receivables | €43.1K | €113.9K |
| Cash & equivalents | €2.6M | €18.9M |
| Total equity | -€19.5M | -€2.2M |
| Non-current liabilities | €10.1M | €13.0M |
| Long-term borrowings | €9.0M | €12.2M |
| Lease liabilities (non-current) | €464.2K | €609.5K |
| Current liabilities | €19.5M | €15.1M |
| Lease liabilities (current) | €268.6K | €307.0K |
| Derived metrics | ||
| Free cash flow | -€29.8M | -€28.2M |
| Operating margin | -4052.7% | -3044.9% |
| Net margin | -4572.4% | -3334.1% |
| Return on equity | 167.3% | 1428.7% |
| Cash conversion ratio | 0.89× | 0.89× |
| Capex coverage | -40.89× | -40.61× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | €482.8K | €42.4K |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€542.8K | -€456.6K |
| Adjustments For Depreciation Expense | €661.3K | €311.5K |
| Adjustments For Finance Costs | €3.3M | €1.9M |
| Adjustments For Income Tax Expense | €465.6K | €386.6K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | -€50.5K | -€102.1K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€905.2K | €990.0K |
| Adjustments For Sharebased Payments | €563.9K | €564.4K |
| Cash Flows From Used In Decrease Increase In Shortterm Deposits and Investments | -€10.6K | €23.6K |
| Comprehensive Income Attributable To Owners of Parent | -€33.0M | -€29.6M |
| Current Accruals and Current Deferred Income Including Current Contract Liabilities | €3.4M | €3.5M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €7.8M | €4.5M |
| Current Contract Liabilities | €170.3K | €164.5K |
| Current Prepaid Expenses | €1.1M | €1.2M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €33.2K | €85.2K |
| Equity and Liabilities | €10.1M | €26.0M |
| Finance Income | €1.1M | €450.6K |
| Gains Losses On Exchange Differences On Translation Net of Tax | -€64.2K | €726.8K |
| General and Administrative Expense | €6.9M | €6.7M |
| Income Taxes Paid Refund Classified As Operating Activities | -€445.9K | -€378.1K |
| Increase Decrease Through Sharebased Payment Transactions | €563.9K | €564.4K |
| Interest Paid Classified As Financing Activities | €928.9K | €314.5K |
| Issue of Equity | €15.8M | €28.4M |
| Issued Capital | €2.9M | €2.5M |
| Noncurrent Financial Assets | €100.4K | €85.7K |
| Noncurrent Recognised Liabilities Defined Benefit Plan | €667.8K | €228.2K |
| Other Comprehensive Income | -€420.1K | €1.1M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€355.9K | €413.4K |
| Other Current Financial Liabilities | €2.8M | €1.6M |
| Other Current Payables | €2.3M | €1.8M |
| Other Current Receivables | €312.9K | €292.3K |
| Other Noncurrent Assets | €1.4M | €782.2K |
| Other Reserves | -€2.9M | -€2.4M |
| Proceeds From Issuing Shares | €15.8M | €28.4M |
| Reserve of Exchange Differences On Translation | €882.2K | €946.4K |
| Retained Earnings | -€206.0M | -€173.5M |
| Sales and Marketing Expense | €1.8M | €2.2M |
| Share Issue Related Cost | €678.2K | €734.8K |
| Share Premium | €185.6M | €170.3M |
| Shortterm Warranty Provision | €80.0K | €71.1K |
| Trade and Other Current Payables To Trade Suppliers | €2.7M | €3.2M |
Every line item above is a fact tagged in Sequana Medical's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.